Antifibroproliferative effect of tenidap in chronic antigen-induced athritis

Arthritis and Rheumatism

Volumn 40, Issue 12, 1997, Pages 2147-2156

  Sánchez Pernaute, Olga ^a   López Armada, Maria José ^a   Hernández, Purificación ^a   Palacios, Itziar ^a   Navarro, Francisco ^b   Martínez, Javier ^c   Egido, Jesús ^a   Herrero Beaumont, Gabriel ^a,d  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^c PFIZER INC   (United States)

^d Division of Rheumatology   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; FIBRONECTIN; MESSENGER RNA; OMEPRAZOLE; TENIDAP; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CELL PROLIFERATION; CHRONIC DISEASE; DRUG EFFECT; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RABBIT; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; CELL DIVISION; CELLS, CULTURED; CHRONIC DISEASE; COLLAGEN; DICLOFENAC; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EXTRACELLULAR MATRIX; FIBRONECTINS; HYPERPLASIA; INDOLES; RABBITS; RNA, MESSENGER; SYNOVIAL MEMBRANE; TRANSFORMING GROWTH FACTOR BETA;

EID: 0031443565     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780401208     Document Type: Article

References (33)

1. Harris ED Jr: Recent insights into the pathogenesis of the proliferative lesion in rheumatoid arthritis. Arthritis Rheum 19: 68-72, 1976
2. Arend WP, Dayer J-M: Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 33:305-315, 1990
3. Delcuran BW: Cytokines in rheumatoid arthritis: localization in arthritic joint tissue and regulation in vitro. Scand J Rheumatol 25:1-38, 1996
4. Raghow R: The role of extracellular matrix in postinflammatory wound healing and fibrosis. FASEB J 8:823-831, 1994
5. Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr: Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 7:1434-1441, 1993
6. Stocker AW, Streuli CH, Martins-Green M, Bissell MJ: Designer microenvironment for the analysis of cell and tissue function. Curr Opin Cell Biol 2:864-874, 1990
7. Blackburn WD Jr, Prupas HM, Silverfield JC, Poiley JE, Caldwell JR, Collins RL, Miller MJ, Sikes DH, Kaplan H, Fleischmann R, Scoville CD, Rutstein JE, Hurd ER, Louie JS, Bankhurst AD, Weaver AL, Sebba AI, Appelrouth DJ, Hudson NP, Sanders KM, Schuette PT, Moidel RA, Kraska AR, Ting N, Shanahan WR Jr, Loose LD: Tenidap in rheumatoid arthritis: a 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone. Arthritis Rheum 38:1447-1456, 1995
8. Sipe JD, Bartle LM, Loose LD: Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen: a possible correlate with clinical acute phase response. J Immunol 148:480-484, 1992
9. Fernandes JC, Martel-Pelletier J, Otterness IG, Lopez-Anaya A, Mineau F, Tardif G, Pelletier J-P: Effects of tenidap on canine experimental osteoarthritis. I. Morphologic and metalloprotease analysis. Arthritis Rheum 38:1290-1303, 1995
10. Lewthwaite J, Blake S, Thompson RC, Hardingham TE, Henderson B: Antifibrotic action of interleukin-1 receptor antagonist in lapine monoarticular arthritis. Ann Rheum Dis 54:591-596, 1995
11. Howson P, Shepard N, Mitchell N: The antigen induced arthritis model: the relevance of the method of induction to its use as a model of human disease. J Rheumatol 13:379-385, 1986
12. Caldwell JR, Kirby DS, Gardner MJ, Hansen RA: The effects of age and gender on the pharmacokinetics of tenidap sodium in patients with rheumatoid arthritis and osteoarthritis. Br J Clin Pharmacol 39S1:3S-9S, 1995
13. Consden R, Doble A, Glynn LE, Nind AP: Production of a chronic arthritis with ovalbumin: its retention in the rabbit knee joint. Ann Rheum Dis 30:307-315, 1971
14. Gutierrez S, Palacios I, Egido J, Zarco P, Miguelez R, Gonzalez E, Herrero-Beaumont G: IL-1β and IL-6 stimulate the production of platelet activating factor by cultured rabbit synovial cells. Clin Exp Immunol 99:364-368, 1995
15. Wilkinson LS, Pitsillides AA, Worrall JG, Edwards JCW: Light microscopic characterization of the fibroblast-like synovial intimai cell (synoviocyte). Arthritis Rheum 35:1179-1184, 1992
16. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987
17. Glynn LE: The chronicity of inflammation and its significance in rheumatoid arthritis. Ann Rheum Dis 27:105-121, 1968
18. Ashhurst DE, Bland YS, Levick JR: An immunohistochemical study of the collagens of rabbit synovial interstitium. J Rheumatol 18:1669-1672, 1991
19. Gay S, Gay RE, Miller EJ: The collagens of the joint. Arthritis Rheum 23:937-941, 1980
20. Linck G, Stocker S, Grimaud JA, Porte A: Distribution of immunoreactive fibronectin and collagen (type I, III, IV) in mouse joints: fibronectin, an essential component of the synovial cavity border. Histochemistry 77:323-328, 1983
21. Kovacs EJ, DiPietro LA: Fibrogenic cytokines and connective tissue production. FASEB J 8:854-861, 1994
22. Scott DL, Delamere JP, Walton KW: The distribution of fibronectin in the pannus in rheumatoid arthritis. Br J Exp Pathol 62:362-367, 1981
23. Wahl SM, Allen JB, Hines KL, Imamichi T, Wahl AM, Furcht LT, McCarthy JB: Synthetic fibronectin peptides suppress arthritis in rats by interrupting leukocyte adhesion and recruitment. J Clin Invest 94:655-662, 1994
24. Mattey DL, Evans E, Dawes PT: The effects of tenidap on cytokine induced proliferation of human synovial fibroblasts in vitro. Ann Rheum Dis 53:250-255, 1994
25. Palacios I, Sánchez-Pernaute O, López-Armada MJ, Hernández P, Miguélez R, Egido J, Herrero-Beaumont G: Tenidap decreases the MCP-1 and IL-8 mRNA expression in the synovial tissue of rabbits with antigen arthritis and in cultured synovial cells (abstract). Arthritis Rheum 39 (suppl 9):S130, 1996
26. 4 and prostanoid synthesis in human polymorphonuclear leukocytes in vitro. Eicosanoids 1:35-39, 1988
27. Hilliquin P, Guinot P, Chermat-Izard V, Puechal X, Menkes CJ: Treatment of rheumatoid arthritis with platelet activating factor antagonist BN 50730. J Rheumatol 22:1651-1654, 1995
28. Ruiz-Ortega M, Largo R, Bustos C, Gómez-Garre D, Egido J: Platelet activating factor stimulates gene expression and synthesis of matrix proteins in cultured rat and human mesangial cells: role of transforming growth factor-β . J Am Soc Nephrol 8:1266-1275, 1997
29. Kawakami A, Eguchi K, Matsuoka N, Tsuboi M, Kawabe Y, Aoyagi T, Nagataki S: Inhibition of Fas antigen-mediated apoptosis of rheumatoid synovial cells in vitro by transforming growth factor β1. Arthritis Rheum 39:1267-1276, 1996
30. McNiff P, Svensson L, Pazoles CJ, Gabel CA: Tenidap modulates cytoplasmic pH and inhibits anion transport in vitro. I. Mechanism and evidence of functional significance. J Immunol 153:2180-2193, 1994
31. Bondeson J: Effects of tenidap on intracellular signal transduction and the induction of proinflammatory cytokines: a review. Gen Pharmacol 27:943-956, 1996
32. Cosgaya JM, Aranda A: Ras- and Raf-mediated regulation of transforming growth factor β1 gene expression by ligands of tyrosine kinase receptors in PC12 cells. Oncogene 12:2651-2660, 1996
33. Madhok R: Tenidap. Lancet 346:481-485, 1995